Risk of incident diabetes in patients with gout: A cohort study

Arthritis and Rheumatology

Volumn 67, Issue 1, 2015, Pages 273-280

  Kim, Seoyoung C ^a   Liu, Jun ^a   Solomon, Daniel H ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; COLCHICINE; CYCLOOXYGENASE 2 INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FEBUXOSTAT; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; PROBENECID; STEROID;

ADULT; ARTICLE; COHORT ANALYSIS; COMORBIDITY; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; GOUT; HEALTH CARE UTILIZATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; OSTEOARTHRITIS; RISK; SEX DIFFERENCE; STEROID THERAPY; AGED; COMPARATIVE STUDY; COMPLICATION; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; RISK FACTOR; UNITED STATES;

AGED; COHORT STUDIES; DIABETES MELLITUS; FEMALE; FOLLOW-UP STUDIES; GOUT; HUMANS; INCIDENCE; MALE; MIDDLE AGED; OSTEOARTHRITIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; SEX FACTORS; UNITED STATES;

EID: 84919922402     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.38918     Document Type: Article

References (29)

1. Choi HK, Mount DB, Reginato AM,. Pathogenesis of gout. Ann Intern Med 2005; 143: 499-516.
2. Zhu Y, Pandya B, Choi H,. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008. Arthritis Rheum 2011; 63: 3136-41.
3. Choi HK, Ford ES,. Prevalence of the metabolic syndrome in individuals with hyperuricemia. Am J Med 2007; 120: 442-7.
4. Choi HK, Ford ES, Li C, Curhan G,. Prevalence of the metabolic syndrome in patients with gout: the Third National Health and Nutrition Examination Survey. Arthritis Rheum 2007; 57: 109-15.
5. Lai HM, Chen CJ, Su BY, Chen YC, Yu SF, Yen JH, et al. Gout and type 2 diabetes have a mutual inter-dependent effect on genetic risk factors and higher incidences. Rheumatology (Oxford) 2012; 51: 715-20.
6. Krishnan E, Akhras KS, Sharma H, Marynchenko M, Wu EQ, Tawk R, et al. Relative and attributable diabetes risk associated with hyperuricemia in US veterans with gout. QJM 2013; 106: 721-9.
7. Krishnan E, Pandya BJ, Chung L, Hariri A, Dabbous O,. Hyperuricemia in young adults and risk of insulin resistance, prediabetes, and diabetes: a 15-year follow-up study. Am J Epidemiol 2012; 176: 108-16.
8. Sui X, Church TS, Meriwether RA, Lobelo F, Blair SN,. Uric acid and the development of metabolic syndrome in women and men. Metabolism 2008; 57: 845-52.
9. Ryu S, Song J, Choi BY, Lee SJ, Kim WS, Chang Y, et al. Incidence and risk factors for metabolic syndrome in Korean male workers, ages 30 to 39. Ann Epidemiol 2007; 17: 245-52.
10. Choi HK, De Vera MA, Krishnan E,. Gout and the risk of type 2 diabetes among men with a high cardiovascular risk profile. Rheumatology (Oxford) 2008; 47: 1567-70.
11. De Vera MA, Rahman MM, Bhole V, Kopec JA, Choi HK,. Independent impact of gout on the risk of acute myocardial infarction among elderly women: a population-based study. Ann Rheum Dis 2010; 69: 1162-4.
12. Grayson PC, Kim SY, LaValley M, Choi HK,. Hyperuricemia and incident hypertension: a systematic review and meta-analysis. Arthritis Care Res (Hoboken) 2011; 63: 102-10.
13. Kim SY, Guevara JP, Kim KM, Choi HK, Heitjan DF, Albert DA,. Hyperuricemia and coronary heart disease: a systematic review and meta-analysis. Arthritis Care Res (Hoboken) 2010; 62: 170-80.
14. Puig JG, Michan AD, Jimenez ML, Pérez de Ayala C, Mateos FA, Capitán CF, et al. Female gout. Clinical spectrum and uric acid metabolism. Arch Intern Med 1991; 151: 726-32.
15. Lally EV, Ho G Jr, Kaplan SR,. The clinical spectrum of gouty arthritis in women. Arch Intern Med 1986; 146: 2221-5.
16. Meisinger C, Thorand B, Schneider A, Stieber J, Döring A, Löwel H,. Sex differences in risk factors for incident type 2 diabetes mellitus: the MONICA Augsburg cohort study. Arch Intern Med 2002; 14;162: 82-9.
17. Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S,. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol 2011; 64: 749-59.
18. Rothman K, Greenland S, Lash T,. Modern Epidemiology. 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 2008.
19. Cox D,. Regression models and life-tables. J R Stat Soc 1972; 34: 187-220.
20. Kleinbaum D, Klein M,. Evaluating the proportional hazards assumption. In:, Gail M, Krickeberg M, Samet JM, Tsiatis A, Wong W, editors. Survival analysis: a self-learning text. Third ed. New York: Springer; 2012. p. 161-200.
21. Carnethon MR, Fortmann SP, Palaniappan L, Duncan BB, Schmidt MI, Chambless LE,. Risk factors for progression to incident hyperinsulinemia: the Atherosclerosis Risk in Communities Study, 1987-1998. Am J Epidemiol 2003; 158: 1058-67.
22. Niskanen L, Laaksonen DE, Lindstrom J, Eriksson JG, Keinanen-Kiukaanniemi S, Ilanne-Parikka P, et al. Serum uric acid as a harbinger of metabolic outcome in subjects with impaired glucose tolerance: the Finnish Diabetes Prevention Study. Diabetes Care 2006; 29: 709-11.
23. Festa A, D'Agostino R Jr, Tracy RP, Haffner SM, for the Insulin Resistance Atherosclerosis Study. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the Insulin Resistance Atherosclerosis Study. Diabetes 2002; 51: 1131-7.
24. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM,. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001; 286: 327-34.
25. Herder C, Peltonen M, Koenig W, Kräft I, Müller-Scholze S, Martin S, et al. Systemic immune mediators and lifestyle changes in the prevention of type 2 diabetes: results from the Finnish Diabetes Prevention Study. Diabetes 2006; 55: 2340-6.
26. Schmidt MI, Duncan BB, Sharrett AR, Lindberg G, Savage PJ, Offenbacher S, et al. Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): a cohort study. Lancet 1999; 353: 1649-52.
27. Shelmadine B, Bowden RG, Wilson RL, Beavers D, Hartman J,. The effects of lowering uric acid levels using allopurinol on markers of metabolic syndrome in end-stage renal disease patients: a pilot study. Anadolu Kardiyol Derg 2009; 9: 385-9.
28. Feig DI, Soletsky B, Johnson RJ,. Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. JAMA 2008; 300: 924-32.
29. Terawaki H, Nakayama M, Miyazawa E, Murata Y, Nakayama K, Matsushima M, et al. Effect of allopurinol on cardiovascular incidence among hypertensive nephropathy patients: the Gonryo study. Clin Exp Nephrol 2013; 17: 549-53.